Case Report: Anti-glomerular basement membrane disease during pregnancy with favorable renal outcome, sequential biopsies, and dual anti-α1/α3(IV) and anti-LM521 antibodies - Report - MDSpire
Advertisement
Case Report: Anti-glomerular basement membrane disease during pregnancy with favorable renal outcome, sequential biopsies, and dual anti-α1/α3(IV) and anti-LM521 antibodies
This case study highlights a rare instance of anti-GBM disease during pregnancy, demonstrating positive renal outcomes following intensive immunosuppressive therapy and pregnancy termination. Sequential kidney biopsies revealed a significant reduction in active necrotizing lesions, underscoring the importance of early intervention.
Background
Anti-glomerular basement membrane (anti-GBM) disease during pregnancy is a rare but serious condition that poses significant risks to both maternal and fetal health. The complexity of managing this disease is compounded by the need for timely diagnosis and effective treatment strategies, which are often hindered by conventional diagnostic methods. Understanding the histopathological evolution of this disease is crucial for optimizing therapeutic approaches and improving patient outcomes.
Data Highlights
Clinical Indicator
Value
Initial Serum Creatinine
5.58 mg/dL
Peak Serum Creatinine
9.79 mg/dL
Active Necrotizing Lesions (Initial Biopsy)
64.3%
Active Necrotizing Lesions (Post-Treatment Biopsy)
30.8%
Key Findings
Early intensive immunosuppression combined with pregnancy termination can halt disease progression in anti-GBM disease during pregnancy.
Sequential kidney biopsies provide valuable insights into the dynamic histopathological changes in anti-GBM disease.
Circulating autoantibodies against type IV collagen α1/α3 chains and laminin-521 were identified, representing a novel finding in this context.
Multidisciplinary management, including plasma exchange and high-dose glucocorticoids, is essential for improving renal outcomes.
Histological evidence supports the potential for renal recovery following timely intervention.
Clinical Implications
Clinicians should consider early and aggressive immunosuppressive therapy in cases of anti-GBM disease during pregnancy to improve maternal and fetal outcomes. The identification of specific autoantibodies may guide treatment decisions and enhance understanding of disease mechanisms.
Conclusion
This case underscores the critical need for prompt diagnosis and intervention in pregnancy-associated anti-GBM disease, highlighting the potential for renal recovery with appropriate management strategies.
